JP2004516013A - 血管形成に関連する障害を診断及び治療するための組成物と方法 - Google Patents

血管形成に関連する障害を診断及び治療するための組成物と方法 Download PDF

Info

Publication number
JP2004516013A
JP2004516013A JP2002514188A JP2002514188A JP2004516013A JP 2004516013 A JP2004516013 A JP 2004516013A JP 2002514188 A JP2002514188 A JP 2002514188A JP 2002514188 A JP2002514188 A JP 2002514188A JP 2004516013 A JP2004516013 A JP 2004516013A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
pro3
sequence
pro polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002514188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516013A5 (enExample
Inventor
ベーカー，ケヴィン，ピー．
フェララ，ナポレオン
ゲルバー，ハンズピーター
ジェリッツェン，メアリー，イー．
ゴッダード，オードリー
ジェー． ゴドウスキー，ポール
エル． ガーニー，オースティン
ヒラン，ケネス，ジェー．
エー． マースターズ，スコット
パン，ジェームス
パオニ，ニコラス，エフ．
ステファン，ジーン−フィリップ，エフ．
ワタナベ，コリン，ケー．
ウィリアムズ，ピー．，ミッキー
ウッド，ウィリアム，アイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/en
Priority claimed from US09/643,657 external-priority patent/US6642024B1/en
Priority claimed from PCT/US2000/023522 external-priority patent/WO2001016319A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/en
Priority claimed from US09/747,259 external-priority patent/US6569645B2/en
Priority claimed from US09/767,609 external-priority patent/US20020042367A1/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from PCT/US2001/006666 external-priority patent/WO2001066740A2/en
Priority claimed from US09/816,744 external-priority patent/US6579520B2/en
Priority claimed from US09/828,366 external-priority patent/US20020010137A1/en
Priority claimed from US09/854,280 external-priority patent/US7115398B2/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/en
Priority claimed from US09/866,028 external-priority patent/US6642360B2/en
Priority claimed from US09/866,034 external-priority patent/US20030170864A1/en
Priority claimed from PCT/US2001/017443 external-priority patent/WO2002016611A2/en
Priority claimed from US09/870,574 external-priority patent/US6551799B2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/en
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2004516013A publication Critical patent/JP2004516013A/ja
Publication of JP2004516013A5 publication Critical patent/JP2004516013A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2002514188A 2000-07-20 2001-07-09 血管形成に関連する障害を診断及び治療するための組成物と方法 Withdrawn JP2004516013A (ja)

Applications Claiming Priority (36)

Application Number Priority Date Filing Date Title
US21955600P 2000-07-20 2000-07-20
US22062400P 2000-07-25 2000-07-25
US22066400P 2000-07-25 2000-07-25
PCT/US2000/020710 WO2001009327A2 (en) 1999-07-28 2000-07-28 Method of preventing the injury or death of retinal cells and treating ocular diseases
US22269500P 2000-08-02 2000-08-02
US09/643,657 US6642024B1 (en) 1998-01-29 2000-08-17 Guanylate-binding protein
PCT/US2000/023522 WO2001016319A2 (en) 1999-08-31 2000-08-23 Compositions and methods for the treatment of immune related diseases
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US23097800P 2000-09-07 2000-09-07
US66461000A 2000-09-18 2000-09-18
US66535000A 2000-09-18 2000-09-18
US24292200P 2000-10-24 2000-10-24
US70923800A 2000-11-08 2000-11-08
PCT/US2000/030952 WO2001049715A2 (en) 2000-01-06 2000-11-08 Methods and compositions for inhibiting neoplastic cell growth
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/747,259 US6569645B2 (en) 1999-05-14 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
PCT/US2000/034956 WO2001046420A2 (en) 1999-12-23 2000-12-20 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US09/767,609 US20020042367A1 (en) 1997-11-25 2001-01-22 Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US79649801A 2001-02-28 2001-02-28
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/006666 WO2001066740A2 (en) 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases
US80270601A 2001-03-09 2001-03-09
US80868901A 2001-03-14 2001-03-14
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/828,366 US20020010137A1 (en) 1997-09-18 2001-04-05 Methods and compositions for inhibiting neoplastic cell growth
US09/854,280 US7115398B2 (en) 1998-05-15 2001-05-10 IL-17 homologous polypeptides and therapeutic uses thereof
US09/854,208 US7217412B2 (en) 1998-05-15 2001-05-10 IL-17C related mammalian cytokine polypeptides
PCT/US2001/017092 WO2001092331A2 (en) 2000-05-30 2001-05-25 Compositions and methods for the treatment of immune related diseases
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
US09/866,034 US20030170864A1 (en) 2000-05-30 2001-05-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/017443 WO2002016611A2 (en) 2000-08-24 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US09/870,574 US6551799B2 (en) 1999-12-07 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PCT/US2001/017800 WO2001093983A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Related Child Applications (4)

Application Number Title Priority Date Filing Date
JP2008194678A Division JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194721A Division JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194764A Division JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Division JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Publications (2)

Publication Number Publication Date
JP2004516013A true JP2004516013A (ja) 2004-06-03
JP2004516013A5 JP2004516013A5 (enExample) 2010-07-15

Family

ID=56290165

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2002514188A Withdrawn JP2004516013A (ja) 2000-07-20 2001-07-09 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194721A Withdrawn JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194764A Withdrawn JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194678A Withdrawn JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Expired - Fee Related JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2008194721A Withdrawn JP2009039118A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194764A Withdrawn JP2009039119A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2008194678A Withdrawn JP2009039117A (ja) 2000-07-20 2008-07-29 血管形成に関連する障害を診断及び治療するための組成物と方法
JP2011173336A Expired - Fee Related JP6033531B2 (ja) 2000-07-20 2011-08-08 血管形成に関連する障害を診断及び治療するための組成物と方法

Country Status (5)

Country Link
EP (1) EP1309685A2 (enExample)
JP (5) JP2004516013A (enExample)
AU (1) AU2001271973A1 (enExample)
CA (1) CA2416538A1 (enExample)
WO (1) WO2002008284A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504501A (ja) * 2007-11-21 2011-02-10 アムジエン・インコーポレーテツド Ｗｉｓｅ結合抗体及びエピトープ

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000690A2 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP4357738B2 (ja) 1997-09-12 2009-11-04 アポテック エール エ デ− エス．アー． システインリッチなレセプターであるｔｒａｉｎ
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US7109292B2 (en) 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119113A1 (en) 1999-07-20 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL147902A0 (en) 1999-08-12 2002-08-14 Agensys Inc C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
EP1623992A3 (en) * 1999-09-01 2006-05-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1228208T3 (da) 1999-10-28 2010-11-22 Agensys Inc 36P6D5: udskilt tumorantigen
EP1897945B1 (en) * 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
DK1283214T3 (da) * 2000-04-21 2007-06-11 Fuso Pharmaceutical Ind Hidtil ukendte kollektiner
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2275549A1 (en) * 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
JP2004532609A (ja) 2000-11-03 2004-10-28 ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア プロキネチシンポリペプチド、関連組成物および方法
EP1334179A2 (en) 2000-11-14 2003-08-13 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003215761A1 (en) * 2002-03-22 2003-10-08 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2003220805A1 (en) * 2002-03-28 2003-10-13 Yamanouchi Pharmaceutical Co., Ltd. Antiopoietin-related growth factor
NZ535925A (en) * 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003261911A1 (en) * 2002-09-04 2004-03-29 Takeda Pharmaceutical Company Limited Use of disease-associated gene
AU2003267096B9 (en) * 2002-09-11 2010-11-11 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) * 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
EP1734998A2 (en) 2004-04-14 2006-12-27 Genentech, Inc. Compositions and methods comprising an egfl7 antagonist for modulating vascular development
SI1781682T1 (sl) 2004-06-24 2013-05-31 Mayo Foundation For Medical Education And Research B7-H5, so-stimulatorni polipeptid
CN101010342A (zh) 2004-07-02 2007-08-01 健泰科生物技术公司 用于治疗非何杰金淋巴瘤的组合物和方法
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
CN106084054A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
LT2280996T (lt) 2008-05-06 2016-12-12 Genentech, Inc. Subrendusio giminingumo crig variantai
HRP20231525T1 (hr) 2009-02-20 2024-03-15 Astellas Pharma Inc. Postupci i pripravci za dijagnozu i liječenje raka
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
WO2010129904A1 (en) 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same
AT508569A1 (de) 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
HUE035516T2 (en) 2009-11-11 2018-05-28 Ganymed Pharmaceuticals Gmbh Antibodies specific to Claulin-6 (CLDN6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
JP6276176B2 (ja) 2011-05-13 2018-02-07 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のための抗体
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014111458A2 (en) * 2013-01-17 2014-07-24 Medizinische Hochschule Hannover Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
NZ722377A (en) 2014-01-24 2022-09-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
GB201906052D0 (en) * 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046281A2 (en) * 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2000053750A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015792A2 (en) * 1998-09-14 2000-03-23 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2002000690A2 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO1999010363A1 (en) * 1997-08-29 1999-03-04 Human Genome Sciences, Inc. 29 human secreted proteins
WO2000053751A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1056847A2 (en) * 1998-02-27 2000-12-06 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
WO1999050405A1 (en) * 1998-03-31 1999-10-07 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
ATE458050T1 (de) * 1998-12-01 2010-03-15 Genentech Inc Promotion oder inhibition von angiogenese und kardiovaskularisation
AU2883600A (en) * 1999-03-08 2000-09-28 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046281A2 (en) * 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2000053750A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504501A (ja) * 2007-11-21 2011-02-10 アムジエン・インコーポレーテツド Ｗｉｓｅ結合抗体及びエピトープ

Also Published As

Publication number Publication date
WO2002008284A2 (en) 2002-01-31
JP6033531B2 (ja) 2016-11-30
WO2002008284A3 (en) 2003-03-13
AU2001271973A1 (en) 2002-02-05
JP2012005493A (ja) 2012-01-12
EP1309685A2 (en) 2003-05-14
JP2009039118A (ja) 2009-02-26
JP2009039117A (ja) 2009-02-26
JP2009039119A (ja) 2009-02-26
CA2416538A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
JP6033531B2 (ja) 血管形成に関連する障害を診断及び治療するための組成物と方法
US7250495B2 (en) PRO20044 polypeptides
US7265210B2 (en) Anti-PRO9821 antibodies
US20040043927A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004506413A (ja) 血管形成に関与する疾患の診断と治療のための組成物と方法
US7312303B2 (en) Anti-PRO4980 antibodies
JP4451059B2 (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US20060073552A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060074033A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20070191270A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030224984A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20060073558A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2042597A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2075253A1 (en) Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
JP2015037408A (ja) 血管形成に関連する障害を診断及び治療するための組成物と方法
HK1149590A (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120313

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120413

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130612

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131001